Headlines about Seattle Genetics (NASDAQ:SGEN) have trended somewhat positive on Wednesday, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Seattle Genetics earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.8917115309199 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern’s scoring:
- Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY) Highlight Interim Results … (streetinsider.com)
- Analysts assigned mean rating score of 2.30 for Seattle Genetics, Inc. (SGEN) – Wall Street Morning (wallstreetmorning.com)
- Seattle Genetics, Inc. (NASDAQ: SGEN) – Active Mover – Alpha Beta Stock (alphabetastock.com)
- Seattle Genetics, Inc. (SGEN) Revamps Its Position for Performance Measures – Stock News Stop (stockmarketstop.com)
- Why Seattle Genetics, Inc. Fell Today – Motley Fool (fool.com)
SGEN has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Seattle Genetics from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a research note on Tuesday, October 10th. Jefferies Group restated a “buy” rating and issued a $53.00 price objective on shares of Seattle Genetics in a research report on Thursday, September 14th. Guggenheim restated a “buy” rating and issued a $72.00 price objective on shares of Seattle Genetics in a research report on Monday, October 23rd. HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of Seattle Genetics in a research report on Friday, October 27th. Finally, TheStreet upgraded shares of Seattle Genetics from a “d” rating to a “c” rating in a research report on Thursday, November 16th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Seattle Genetics currently has an average rating of “Hold” and a consensus price target of $63.76.
Seattle Genetics (NASDAQ:SGEN) last issued its earnings results on Thursday, October 26th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.23. Seattle Genetics had a negative net margin of 26.53% and a negative return on equity of 32.41%. The company had revenue of $135.29 million during the quarter, compared to analysts’ expectations of $112.76 million. During the same period last year, the company posted ($0.23) earnings per share. The firm’s quarterly revenue was up 27.3% compared to the same quarter last year. equities research analysts anticipate that Seattle Genetics will post -0.93 EPS for the current year.
In other news, COO Eric Dobmeier sold 35,000 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $58.25, for a total transaction of $2,038,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Todd E. Simpson sold 39,385 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $60.91, for a total transaction of $2,398,940.35. The disclosure for this sale can be found here. Over the last three months, insiders have sold 138,378 shares of company stock valued at $8,229,957. Corporate insiders own 34.70% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Seattle Genetics (SGEN) Receiving Somewhat Favorable Media Coverage, Accern Reports” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/12/13/seattle-genetics-sgen-receiving-somewhat-favorable-media-coverage-accern-reports.html.
Seattle Genetics Company Profile
Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).
Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.